速效抗晕胶囊质量标准研究

目的 确定速效抗晕胶囊的质量检测标准.方法 采用薄层色谱法定性鉴别干姜提取物,用高效液相色谱法测定硫酸右旋苯丙胺和茶苯海明含量.结果 薄层色谱法鉴别专属性强;高效液相色谱法中,硫酸右旋苯丙胺在244～366μg/ml范围内浓度与吸收度呈良好线性关系(r=0.9999),平均回收率为99.54%,RSD为0.81%;茶苯...     

HPLC法测定索咪新尿素乳膏中丙酸氯倍他索和硝酸咪康唑的含量

目的采用高效液相色谱法(HPLC)测定索咪新尿素乳膏中丙酸氯倍他索和硝酸咪康唑的含量。方法采用Diamonsil C18柱(150 mm×4.6 mm,5μm)为色谱柱,以甲醇-0.1%醋酸铵溶液(80∶20)为流动相,以苯甲酸苄酯为内标,流速为1.0 mL/min,紫外检测器于240 nm测定。结果 HPLC法测定,样品与基质分离良好,丙酸氯倍他索和硝酸咪康唑的线性范围分别为7.5～12.5 mg/L和0.3～0.5 mg/mL内(r=0.9999),平均回收率均>98.00%,样品溶液在48 h内稳定。结论 HPLC法简便、准确、灵敏、重现性好,能有效控制索咪新尿素乳膏的内在质量。     

152例重度子痫前期产后使用硫酸镁的疗效分析

目的：本研究旨在探讨重度子痫前期患者产后使用硫酸镁的时长,观察其临床效果。方法：回顾性分析2007年1月～2010年1月在本院产科分娩、符合子痫前期重度诊断标准的产妇152例,将152例患者分为硫酸镁产后2天停药组（83例）和硫酸镁产后5天停药组（69例）。对两组患者停药后的自觉症状、体征、检验值以及病情反复情况进行比较;对两组患者停药后的病情反复情况进行比较。结果：两组产妇的疾病严重程度、血压水平及抗高血压治疗均无差异,两组资料具有可比性。两组患者硫酸镁停药后的疗效对比,肾功异常的差异无显著性（P〉0．05）,停药后头痛、眼花、胸闷、胸腹水、水肿、蛋白尿、尿颗粒管型及停药病情反复情况差异有统计学意义（P〈0．05）;两组患者硫酸镁不同停药时长病情反复的比较,两样本病情反复频率的差别具有统计学意义（P〈0．05）。结论：硫酸镁对重度子痫前期的疗效确切,但产后硫酸镁治疗持续时间维持五天可明显降低重度子痫前期患者病情反复以及子痫的发生,预后良好,无不良结局发生。     

海参硫酸软骨素抑制小鼠Lewis肺癌生长和转移作用的研究

目的探讨海参硫酸软骨素(sea cucumber chondroitin sulfate,SC-CHS)对小鼠肿瘤生长和转移的抑制作用及其机制。方法建立C57 BL/6J小鼠Lewis肺癌自发性肺转移模型,连续腹腔注射给药21 d,剥离原位肿瘤和双侧肺,分别称瘤重和计数肺表面转移灶结节数;分离血清,ELISA法检测小鼠血清中肿瘤坏死因子-α(tumornecrosis factor-α,TNF-α)和γ-干扰素(γ-interferon,γ-IFN)的含量;采用RT-PCR法检测肿瘤组织中缺氧诱导因子(hypoxia inducible factor-1α,HIF-1α)、血管内皮生长因子(vascular endothelial growth factor,VEGF)、乙酰肝素酶(heparanase,Hpa)mRNA的表达。结果 SC-CHS可以显著抑制荷瘤小鼠肿瘤的生长,其平均抑制率为31.5%,并可以显著减少肺表面转移灶结节数(P<0.01),平均抑制率为42.3%;SC-CHS可以显著提高血清中TNF-α和γ-IFN的含量(P<0.05),降低荷瘤小鼠肿瘤组织中HIF-1α、VEGF、Hpa mRNA的表达(P<0.05)。结论 SC-CHS能显著抑制肿瘤细胞在小鼠体内的生长和转移,其机制可能与抑制肿瘤血管新生,提高机体免疫力有关。     

Comparison of Foaming Properties Between the Shirasu Porous Glass Membrane Device and Tessari’s Three-way Stopcock Technique for Polidocanol and Ethanolamine Oleate Foam Production: A Benchtop Study

PurposeTo compare the characteristics of polidocanol (POL) and ethanolamine oleate (EO) sclerosing foams produced by a Shirasu porous glass membrane (SPGM) device with those made using a 3-way stopcock (3WSC).Materials and MethodsFoam half-life times were measured in an ex-vivo benchtop study. Computed tomography (CT) images of each foam were obtained over the time course, and a CT texture analysis was conducted. The bubble size in each foam was measured by an optical microscope.ResultsMedian foam half-life times were longer in the SPGM group than in the 3WSC group (POL: 198 vs 166 s, P = .02; EO: 640 vs 391 s, P < .01). In the CT texture analysis, median standard deviation (SD) and entropy (randomness) were lower, and median energy (uniformity) and gray-level cooccurrence matrix (GLCM) homogeneity were higher in the SPGM group than in the 3WSC group (POL SD: at 30 s and 50–300 s; POL entropy: at 0–60 s; EO SD: at 0–600 s; EO entropy: at 0–460 s; POL energy: at 0–40 s; POL GLCM homogeneity: at 0–250 s; EO energy: at 0–360 s; EO GLCM homogeneity: at 0–480 s; all P < .05). Median bubble diameters in the SPGM group and in the 3WSC group were 69 and 83 μm (P < .01), respectively, in the POL foam; and 36 and 36 μm (P = .45), respectively, in the EO foam.ConclusionsPOL and EO foams had greater uniformity and longer foam half-life time when prepared with an SPGM device than with a 3WSC.     

头孢洛扎硫酸盐制备方法的改进

将起始原料ACLE·HCl首先与7-位侧链噻二唑化合物TATD反应，然后再与吡唑化合物UBT进行反应，并用三氟乙酸进行脱保护基反应。最后经过纯化析晶，合成头孢洛扎硫酸盐。该工艺得到头孢洛扎硫酸盐的纯度高，原料易得，纯化时不需要过柱，更适合工业化生产。     

Mechanochemical Endovenous Ablation of Varicose Veins in Pediatric Patients with Klippel-Trénaunay Syndrome: Feasibility,Safety, and Initial Results

PurposeTo evaluate feasibility, safety, and results of endovenous mechanochemical ablation (MOCA) for treatment of persistent embryonic and dysplastic veins in pediatric patients with Klippel-Trénaunay syndrome (KTS).Materials and MethodsThirteen MOCA procedures were performed in 11 patients (age range, 4–16 years) with KTS and symptomatic persistent embryonic or dysplastic veins during a 24-month period. All patients were evaluated with color Doppler (CD) ultrasound (US), contrast-enhanced MR imaging, and venography to assess the anatomy of the target vessels and patency of the deep venous system. All procedures were performed under general anesthesia with a ClariVein catheter and liquid sodium tetradecyl sulfate as the sclerosing agent. US and fluoroscopic guidance were used in all cases. Technical success rate, primary occlusion rate, adverse effects, and recanalization rates were evaluated. Clinical and radiological (CD US) controls were performed 1 day, 7 days, 1 month, and 6 months after the procedure and once a year thereafter, with a mean follow-up of 16 months (range, 6–25 months).ResultsTechnical success and primary occlusion were achieved in all patients with no adverse events. During the follow-up period, CD US demonstrated partial recanalization and symptom recurrence in 2 patients (18%), 14 and 18 months after the initial procedure. These 2 patients had a second ablation procedure with no recanalization or symptom recurrence during the subsequent follow-up period.ConclusionsMOCA is feasible and appears to be a safe and effective technique for treatment of varicose veins in pediatric patients with KTS.     

Three-year efficacy and patency follow-up of decellularized human internal mammary artery as a novel vascular graft in animal models

Background

Various investigations have reported that the internal mammary artery (IMA) is an efficient and functional choice of conduit for vascular graft surgeries, especially for coronary artery bypass grafts; however, the quest to find an ideal vascular substitute remains. We hypothesized that acellular IMA could be an appropriate graft for small-diameter vascular bypasses that could be used in various surgeries including coronary artery bypass grafting.